Humasis Co. Ltd
Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface protei… Read more
Humasis Co. Ltd (205470) - Net Assets
Latest net assets as of September 2025: ₩248.94 Billion KRW
Based on the latest financial reports, Humasis Co. Ltd (205470) has net assets worth ₩248.94 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩339.69 Billion) and total liabilities (₩90.75 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩248.94 Billion |
| % of Total Assets | 73.28% |
| Annual Growth Rate | 46.4% |
| 5-Year Change | 369.41% |
| 10-Year Change | N/A |
| Growth Volatility | 116.3 |
Humasis Co. Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Humasis Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Humasis Co. Ltd (2016–2024)
The table below shows the annual net assets of Humasis Co. Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩229.26 Billion | -20.21% |
| 2023-12-31 | ₩287.33 Billion | -17.13% |
| 2022-12-31 | ₩346.73 Billion | +71.65% |
| 2021-12-31 | ₩202.01 Billion | +313.60% |
| 2020-12-31 | ₩48.84 Billion | +220.39% |
| 2019-12-31 | ₩15.24 Billion | -5.47% |
| 2018-12-31 | ₩16.13 Billion | +3.40% |
| 2017-12-31 | ₩15.60 Billion | +43.58% |
| 2016-12-31 | ₩10.86 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Humasis Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4990592.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩247.89 Billion | 108.13% |
| Common Stock | ₩12.97 Billion | 5.66% |
| Total Equity | ₩229.26 Billion | 100.00% |
Humasis Co. Ltd Competitors by Market Cap
The table below lists competitors of Humasis Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JTC Inc
KQ:950170
|
$49.02 Million |
|
CrystalGenomics Inc
KQ:083790
|
$49.02 Million |
|
AstroNova Inc
NASDAQ:ALOT
|
$49.05 Million |
|
China Fineblanking Technology Co Ltd
TWO:1586
|
$49.06 Million |
|
NEBAG NA SF 0,02
F:NWR
|
$48.96 Million |
|
Precise Corporation Public Company Limited
BK:PCC
|
$48.96 Million |
|
Titanium Transportation Group Inc.
TO:TTNM
|
$48.94 Million |
|
Inhibikase Therapeutics Inc
NASDAQ:IKT
|
$48.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Humasis Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 287,326,533,900 to 229,263,033,480, a change of -58,063,500,420 (-20.2%).
- Net loss of 30,441,718,730 reduced equity.
- Share repurchases of 26,974,419,060 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-30.44 Billion | -13.28% |
| Share Repurchases | ₩26.97 Billion | -11.77% |
| Other Changes | ₩-647.36 Million | -0.28% |
| Total Change | ₩- | -20.21% |
Book Value vs Market Value Analysis
This analysis compares Humasis Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.38x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1922.46 | ₩761.00 | x |
| 2017-12-31 | ₩148.09 | ₩761.00 | x |
| 2018-12-31 | ₩143.92 | ₩761.00 | x |
| 2019-12-31 | ₩541.66 | ₩761.00 | x |
| 2020-12-31 | ₩1428.33 | ₩761.00 | x |
| 2021-12-31 | ₩1476.91 | ₩761.00 | x |
| 2022-12-31 | ₩2706.20 | ₩761.00 | x |
| 2023-12-31 | ₩2258.63 | ₩761.00 | x |
| 2024-12-31 | ₩2026.12 | ₩761.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Humasis Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -13.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -119.79%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.45x
- Recent ROE (-13.28%) is below the historical average (8.75%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.03% | 0.00% | 0.00x | 0.00x | ₩-2.09 Billion |
| 2015 | 0.65% | 0.00% | 0.00x | 0.00x | ₩-1.99 Billion |
| 2016 | 1.02% | 0.00% | 0.00x | 1.12x | ₩-975.60 Million |
| 2017 | -30.25% | -55.44% | 0.30x | 1.82x | ₩-6.28 Billion |
| 2018 | -5.29% | -8.83% | 0.28x | 2.13x | ₩-2.47 Billion |
| 2019 | -8.04% | -13.40% | 0.25x | 2.39x | ₩-2.75 Billion |
| 2020 | 43.17% | 46.12% | 0.67x | 1.40x | ₩16.20 Billion |
| 2021 | 74.85% | 46.98% | 0.94x | 1.69x | ₩131.00 Billion |
| 2022 | 52.67% | 38.75% | 1.01x | 1.35x | ₩147.95 Billion |
| 2023 | -19.29% | -400.83% | 0.04x | 1.21x | ₩-84.16 Billion |
| 2024 | -13.28% | -119.79% | 0.08x | 1.45x | ₩-53.37 Billion |
Industry Comparison
This section compares Humasis Co. Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $83,772,599,338
- Average return on equity (ROE) among peers: 9.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Humasis Co. Ltd (205470) | ₩248.94 Billion | 0.03% | 0.36x | $48.97 Million |
| Shinhung (004080) | $87.31 Billion | 3.50% | 0.52x | $10.80 Million |
| Osang Healthcare Co.,Ltd (036220) | $199.86 Billion | 20.34% | 0.25x | $37.44 Million |
| HansBiomed Corporation (042520) | $43.16 Billion | 11.38% | 0.21x | $246.58 Million |
| JVM Co. Ltd (054950) | $98.83 Billion | 10.23% | 0.72x | $117.37 Million |
| Huvitz Co. Ltd (065510) | $51.68 Billion | 16.97% | 0.32x | $43.64 Million |
| Vieworks Co. Ltd (100120) | $188.04 Billion | 17.80% | 0.28x | $101.54 Million |
| Corentec Co Ltd (104540) | $48.30 Billion | -3.04% | 0.46x | $40.80 Million |
| Hironic Co. Ltd (149980) | $40.72 Billion | 7.13% | 0.15x | $23.71 Million |
| Laseroptek Co., Ltd. (199550) | $-3.94 Billion | 0.00% | 0.00x | $21.68 Million |